These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 14647053)

  • 1. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients.
    Schiff ER; Lai CL; Hadziyannis S; Neuhaus P; Terrault N; Colombo M; Tillmann HL; Samuel D; Zeuzem S; Lilly L; Rendina M; Villeneuve JP; Lama N; James C; Wulfsohn MS; Namini H; Westland C; Xiong S; Choy GS; Van Doren S; Fry J; Brosgart CL;
    Hepatology; 2003 Dec; 38(6):1419-27. PubMed ID: 14647053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results.
    Schiff E; Lai CL; Hadziyannis S; Neuhaus P; Terrault N; Colombo M; Tillmann H; Samuel D; Zeuzem S; Villeneuve JP; Arterburn S; Borroto-Esoda K; Brosgart C; Chuck S;
    Liver Transpl; 2007 Mar; 13(3):349-60. PubMed ID: 17326221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
    Dai CY; Chuang WL; Hsieh MY; Lee LP; Huang JF; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Tsai JF; Chang WY; Yu ML
    Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
    Marcellin P; Chang TT; Lim SG; Tong MJ; Sievert W; Shiffman ML; Jeffers L; Goodman Z; Wulfsohn MS; Xiong S; Fry J; Brosgart CL;
    N Engl J Med; 2003 Feb; 348(9):808-16. PubMed ID: 12606735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1.
    Benhamou Y; Thibault V; Vig P; Calvez V; Marcelin AG; Fievet MH; Currie G; Chang CG; Biao L; Xiong S; Brosgart C; Poynard T
    J Hepatol; 2006 Jan; 44(1):62-7. PubMed ID: 16274835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
    Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Arterburn S; Xiong S; Currie G; Brosgart CL;
    N Engl J Med; 2005 Jun; 352(26):2673-81. PubMed ID: 15987916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant.
    Yang Y; Zhang Q; Cai CJ; Lu MQ; Li X; Jiang N; Jiang H; Xu C; Li H; Wang GS; Yi SH; Zhang J; Zhang JF; Yi HM; Zhang YC; Chen GH
    Chin Med J (Engl); 2007 Aug; 120(16):1400-3. PubMed ID: 17825167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
    Wiegand J; Tischendorf JJ; Nashan B; Klempnauer J; Flemming P; Niemann P; Rohde P; Manns MP; Trautwein C; Tillmann HL
    Z Gastroenterol; 2004 Jan; 42(1):15-8. PubMed ID: 14997399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants.
    Liu CJ; Kao JH; Chen PJ; Chen TC; Lin FY; Lai MY; Chen DS
    J Viral Hepat; 2006 Jun; 13(6):387-95. PubMed ID: 16842441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.
    Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Wulfsohn MS; Xiong S; Fry J; Brosgart CL;
    N Engl J Med; 2003 Feb; 348(9):800-7. PubMed ID: 12606734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
    N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.
    Perrillo R; Schiff E; Yoshida E; Statler A; Hirsch K; Wright T; Gutfreund K; Lamy P; Murray A
    Hepatology; 2000 Jul; 32(1):129-34. PubMed ID: 10869300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
    Moon JH; Cho M; Yoon KT; Bae JH; Heo J; Kim GH; Kang DH; Song GA
    Korean J Hepatol; 2008 Dec; 14(4):503-12. PubMed ID: 19119245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period].
    Yang Q; Gong ZJ; Hu DF
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):515-9. PubMed ID: 19912686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.
    Peters MG; Hann Hw Hw; Martin P; Heathcote EJ; Buggisch P; Rubin R; Bourliere M; Kowdley K; Trepo C; Gray Df Df; Sullivan M; Kleber K; Ebrahimi R; Xiong S; Brosgart CL
    Gastroenterology; 2004 Jan; 126(1):91-101. PubMed ID: 14699491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients.
    Westland CE; Yang H; Delaney WE; Wulfsohn M; Lama N; Gibbs CS; Miller MD; Fry J; Brosgart CL; Schiff ER; Xiong S
    J Viral Hepat; 2005 Jan; 12(1):67-73. PubMed ID: 15655050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine.
    Manolakopoulos S; Bethanis S; Koutsounas S; Goulis J; Vlachogiannakos J; Christias E; Saveriadis A; Pavlidis C; Triantos C; Christidou A; Papatheodoridis G; Karamanolis D; Tzourmakliotis D
    Aliment Pharmacol Ther; 2008 Feb; 27(3):266-73. PubMed ID: 17988233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients].
    Cho JH; Cheong JY; Kang JK; Park JS; Lee MH; Lim NK; Hong SP; Kim SO; Yoo WD; Cho SW
    Korean J Hepatol; 2008 Mar; 14(1):58-66. PubMed ID: 18367858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance.
    Kim YJ; Paik SW; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Yoo BC
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1454-60. PubMed ID: 22168753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.